Clinical Trials
13 trialsNCT06993675 2026-05-13
ROTATE
Yale University
Phase 2 Recruiting
NCT03192397 2026-04-14
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT05690984 2026-03-16
EMAT
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT02389517 2026-01-22
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Phase 2 Completed
NCT04991103 2025-12-31
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
University of Alabama at Birmingham
Phase 2 Recruiting
NCT02988466 2025-05-28
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT06697483 2024-11-25
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Peking University People's Hospital
Phase NA Recruiting
NCT03524235 2024-11-12
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
Phase 1 Completed
NCT05820763 2024-07-10
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
Phase 2 Withdrawn
NCT05697913 2024-03-06
Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation
Hospital Galdakao-Usansolo
Phase NA Unknown
NCT06158269 2023-12-06
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT03272633 2023-06-26
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Terminated
NCT04309084 2023-02-16
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
Celularity Incorporated
Phase 1 Unknown